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Figure S1. Progesterone Receptor (PGR) mRNA expression in ESR1 mutant cells 
a) MCF-7 WT, ESR1 Y537S, and LTED cells were cultured in MEM media supplemented with 
10% FBS and analyzed by qRT-PCR. PGR was upregulated in ESR1 Y537S and LTED cells 
compared to WT. Error bars represent standard error of the mean (N=3 replicates). One-way 
ANOVA was performed for statistical analysis.  
b) T47D WT and ESR1 Y537S, were cultured in MEM media supplemented with 10% FBS and 
analyzed by qRT-PCR. Error bars represent standard error of the mean (N=3 replicates). 
Student’s t-test was performed for statistical analysis. P<0.05 was considered statistically 




















































































Figure S2. The ER mutant protein is nuclear localized. 
(a) MCF-7 and (b) T47D cells were cultured in 5% charcoal-stripped serum supplemented media 
for 72 hours before harvesting. Subcellular fractionation was performed, and the cytoplasmic 
and nuclear fractions were analyzed by immunoblot. In the immunoblot densitometry analysis, 
cytoplasmic fraction was normalized to GAPDH and the nuclear fraction was normalized to 
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Figure S3. ESR1 mutations in MCF-7 cells. 
(a) ddPCR 2D droplet plots of defined ESR1 mutation vs WT in MCF-7 LTED cells. ESR1 Y537S 
and D538G were not detected in LTED cells. Detection of 3 out of 1000 positive ESR1 mutant 
droplets was defined as positive detection of ESR1 mutation. 
(b) ddPCR 2D droplet plots of defined ESR1 mutation vs WT in MCF-7 WT cells. ESR1 Y537C, 
Y537N, Y537S and D538G mutations were not detected in WT cells. Detection of 3 out of 








































Figure S4. The MCF-7 ESR1 Y537S cell line had global kinase activation. 
MCF-7 WT and ESR1 Y537S cells were cultured in full serum supplemented media and analyzed 
by KiP. Kinase hyperactivation was defined as Y537S-unique and ≥1.5 fold in Y537S cells 
compared to WT. All kinases ≥1.5-fold hyperactivated are shown.  


























































































Figure S5. ET reduced p-RON levels in T47D WT cells and in RON/MSP overexpressing T47D 
cells. 
(a) T47D cells with RON/MSP overexpression (R/M) cells were treated with TM or E2 
deprivation (with or without E2 add-back) and cell lysates were analyzed by immunoblot. 
Blocking estrogen signaling reduced p-RON levels in the T47D R/M model. A description of 
T47D R/M cells is in Cunha et al, Cell Reports 2014.1 
(b) T47D R/M cells were treated with raloxifene, Ful, and tamoxifen (TM) and cell lysates were 











































Figure S6. MCF-7 and T47D cell response to CDK4/6 inhibitors ribociclib and abemaciclib. 
(a) MCF-7 WT, WT PalbR, ESR1 Y537S, and ESR1 Y537S PalbR cells were treated with 1 μM 
ribociclib or abemaciclib for 7 days and growth was analyzed by MTT. Error bars represent 
standard deviation (N=3 replicates). Two-way ANOVA was performed for statistical analysis. 
(b) T47D WT, WT PalbR, ESR1 Y537S, and ESR1 Y537S PalbR cells were treated with 1 μM 
ribociclib or abemaciclib for 7 days and growth was analyzed by MTT. Error bars represent 






















































































































Figure S7. ESR1 mutations are not acquired in MCF-7 WT PalbR cells. 
ddPCR 2D droplet plots of defined ESR1 mutation vs WT in MCF-7 WT PalbR. ESR1 Y537C, 
Y537C, Y537N, and D538G were not detected in MCF-7 WT PalbR cells. Detection of 3 out of 
1000 positive ESR1 mutant droplets was defined as positive detection of ESR1 mutation. 





















0% Y537S 0% D538G 




















Figure S8. MCF-7 WT PalbR and ESR1 Y537S PalbR tumor growth, in vivo. 
MCF-7 WT or WT PalbR xenografts were grown in athymic nude mice that were supplemented with 
E2 drinking water. When primary tumors reached 350 mm3, mice were treated with 125 mg/kg 
palbociclib p.o. 5 days on, 2 days off. The drug effect on primary tumor growth was determined by 
time to tumor doubling from the start of palbociclib treatment. The Mantel-Cox test was used for 
statistical analysis. Shaded circles represent censored events representing primary tumors that had 
not doubled in volume. Median survival is 11.0 weeks for MCF-7 WT (N=11) and 5.0 weeks for MCF-
7 WT PalbR (N=9), p-value = 0.0335. 
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Table S1. MSigDB hallmark pathways upregulated in MCF-7 ESR1 Y537S vs MCF-7 ESR1 WT 
 
Gene Set Name No. Genes P-value FDR q-val 
HALLMARK_INTERFERON_ALPHA_RESPONSE 92 0.0000 0.0000 
HALLMARK_ESTROGEN_RESPONSE_LATE 196 0.0000 0.0000 
HALLMARK_INTERFERON_GAMMA_RESPONSE 196 0.0000 0.0000 
HALLMARK_ESTROGEN_RESPONSE_EARLY 193 0.0000 0.0000 
HALLMARK_E2F_TARGETS 190 0.0000 0.0000 
HALLMARK_MTORC1_SIGNALING 193 0.0000 0.0003 
HALLMARK_CHOLESTEROL_HOMEOSTASIS 71 0.0000 0.0020 
HALLMARK_KRAS_SIGNALING_DN 187 0.0000 0.0024 
HALLMARK_UNFOLDED_PROTEIN_RESPONSE 106 0.0020 0.0069 
HALLMARK_COAGULATION 136 0.0060 0.0071 
HALLMARK_INFLAMMATORY_RESPONSE 197 0.0019 0.0104 
HALLMARK_UV_RESPONSE_UP 152 0.0000 0.0180 
HALLMARK_ALLOGRAFT_REJECTION 195 0.0571 0.1274 
HALLMARK_COMPLEMENT 195 0.0527 0.1302 
HALLMARK_MYC_TARGETS_V2 58 0.0610 0.1224 
HALLMARK_FATTY_ACID_METABOLISM 152 0.0732 0.1409 
HALLMARK_G2M_CHECKPOINT 189 0.0959 0.2002 
HALLMARK_IL6_JAK_STAT3_SIGNALING 87 0.0938 0.1896 
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 195 0.0886 0.1829 
HALLMARK_DNA_REPAIR 141 0.1206 0.2160 
HALLMARK_XENOBIOTIC_METABOLISM 197 0.1260 0.2095 
HALLMARK_P53_PATHWAY 190 0.1376 0.2016 
HALLMARK_KRAS_SIGNALING_UP 192 0.1772 0.2642 
HALLMARK_APICAL_JUNCTION 194 0.2073 0.2557 
HALLMARK_APOPTOSIS 158 0.2231 0.3029 
HALLMARK_BILE_ACID_METABOLISM 112 0.2654 0.3583 
HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY 45 0.3430 0.4143 
HALLMARK_PI3K_AKT_MTOR_SIGNALING 104 0.3507 0.4249 
HALLMARK_PANCREAS_BETA_CELLS 40 0.3758 0.4393 
HALLMARK_MYOGENESIS 197 0.4585 0.5205 
HALLMARK_APICAL_SURFACE 43 0.4852 0.5556 
HALLMARK_ANGIOGENESIS 36 0.6819 0.7387 
HALLMARK_SPERMATOGENESIS 132 0.7000 0.7701 
HALLMARK_WNT_BETA_CATENIN_SIGNALING 42 0.8485 0.8812 
HALLMARK_IL2_STAT5_SIGNALING 194 0.9526 0.9403 
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Table S2. MSigDB hallmark pathways upregulated in MCF-7 LTED vs MCF-7 ESR1 WT 
 
Gene Set Name No. Genes P-value FDR q-val 
HALLMARK_E2F_TARGETS 190 0.0000 0.0000 
HALLMARK_G2M_CHECKPOINT 189 0.0000 0.0000 
HALLMARK_MTORC1_SIGNALING 193 0.0000 0.0000 
HALLMARK_MYC_TARGETS_V1 193 0.0000 0.0000 
HALLMARK_ESTROGEN_RESPONSE_LATE 196 0.0000 0.0027 
HALLMARK_CHOLESTEROL_HOMEOSTASIS 71 0.0065 0.0191 
HALLMARK_INTERFERON_ALPHA_RESPONSE 92 0.0042 0.0187 
HALLMARK_UV_RESPONSE_UP 152 0.0139 0.0344 
HALLMARK_DNA_REPAIR 141 0.0350 0.1019 
HALLMARK_OXIDATIVE_PHOSPHORYLATION 182 0.0458 0.1136 
HALLMARK_MYC_TARGETS_V2 58 0.0509 0.1119 
HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY 45 0.0848 0.1597 
HALLMARK_KRAS_SIGNALING_DN 187 0.0833 0.1537 
HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION 195 0.1188 0.2170 
HALLMARK_ADIPOGENESIS 189 0.1282 0.2220 
HALLMARK_FATTY_ACID_METABOLISM 152 0.1385 0.2146 
HALLMARK_INTERFERON_GAMMA_RESPONSE 196 0.1619 0.2206 
HALLMARK_BILE_ACID_METABOLISM 112 0.3016 0.3754 
HALLMARK_PI3K_AKT_MTOR_SIGNALING 104 0.5456 0.6224 
HALLMARK_SPERMATOGENESIS 132 0.6577 0.7771 
HALLMARK_APICAL_SURFACE 43 0.7228 0.7860 
HALLMARK_XENOBIOTIC_METABOLISM 197 0.7908 0.8275 
HALLMARK_IL6_JAK_STAT3_SIGNALING 87 0.9864 0.9743 
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Table S3. MSigDB hallmark pathways upregulated in T47D ESR1 Y537S vs T47D ESR1 WT 
 
Gene Set Name No. Genes P-value FDR q-val 
HALLMARK_ESTROGEN_RESPONSE_EARLY 193 0.0000 0.0099 
HALLMARK_ESTROGEN_RESPONSE_LATE 196 0.0201 0.0909 
HALLMARK_COAGULATION 136 0.0368 0.1312 
HALLMARK_INTERFERON_ALPHA_RESPONSE 92 0.0326 0.1322 
HALLMARK_KRAS_SIGNALING_DN 187 0.0895 0.2218 
HALLMARK_IL2_STAT5_SIGNALING 194 0.3191 0.6273 
HALLMARK_INTERFERON_GAMMA_RESPONSE 196 0.3452 0.5765 
HALLMARK_WNT_BETA_CATENIN_SIGNALING 42 0.3594 0.5226 
HALLMARK_NOTCH_SIGNALING 32 0.4412 0.5624 
HALLMARK_HYPOXIA 191 0.5193 0.6263 
HALLMARK_COMPLEMENT 195 0.6204 0.6997 
HALLMARK_HEDGEHOG_SIGNALING 35 0.6719 0.6758 
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Table S5. Kinome response to Tam in MCF-7 ESR1 Y537S cells by KiP analysis
Kinase Y537S/WT Y537S Tam/Y537S 
RET 103.33 0.07 
ROR2 16.71 1.28 
MST1R 14.00 0.26 
BMPR2 9.40 0.13 
MAP4K2 8.60 0.00 
SIK3 7.00 0.93 
PTK6 6.35 0.65 
PRKACA 6.06 0.53 
HSPB8 5.60 0.30 
ATM 5.56 0.14 
CDK11B 5.00 0.00 
MAP3K4 5.00 0.00 
CDK4 4.78 0.38 
CSNK1A1 4.75 0.55 
RPS6KA3 4.55 0.33 
CSNK2A2 4.38 0.90 
ATR 4.33 0.00 
JAK1 4.27 0.16 
INSR 4.18 0.46 
PKMYT1 4.15 0.80 
CDK5 4.00 0.63 
PIK3R4 4.00 0.00 
TAOK3 3.67 0.72 
EPHB3 3.61 0.37 
AURKB 3.60 1.24 
CDK3 3.46 0.00 
CDK2 3.45 0.94 
BMP2K 3.33 0.91 
CDC42BPB 3.20 0.00 
TRRAP 3.14 0.27 
MAP2K3 3.10 0.42 
MAP4K4 3.04 0.48 
SYK 2.92 0.50 
RPS6KA2 2.81 0.36 
CAMK2D 2.80 0.82 
Kinase Y537S/WT Y537S Tam/Y537S 
DYRK1A 2.64 0.33 
MAP2K1 2.63 0.64 
MAPK4 2.62 0.55 
MAP4K3 2.55 0.63 
MAPK6 2.50 0.58 
IGF1R 2.47 0.38 
LIMK2 2.44 0.71 
CDK1 2.41 0.79 
CSNK1G1 2.33 0.00 
RPS6KA5 2.33 0.04 
MAPK1 2.23 0.91 
STK4 2.19 0.64 
PDPK1 2.18 0.63 
CASK 2.18 0.18 
EPHB4 2.17 0.31 
BRD4 2.07 0.20 
EIF2AK4 2.05 0.00 
PRKCH 2.00 2.13 
EIF2AK3 1.94 0.00 
CDK7 1.83 0.62 
VRK2 1.80 0.94 
CLK2 1.77 0.72 
MAPK3 1.76 0.66 
TYK2 1.74 0.41 
CAMK2B 1.64 0.64 
ABL1 1.64 0.42 
STK3 1.63 0.57 
MAP3K3 1.61 0.72 
IKBKB 1.60 0.09 
PLK1 1.59 0.27 
CDK9 1.58 0.90 
PKN2 1.57 0.00 
TESK1 1.55 0.69 
ULK3 1.51 0.74 
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Extended Materials and Methods 
 
Cell Culture 
MCF-7 cells were cultured in MEM (Corning, Tewksbury, MA) supplemented with 10% FBS 
(Gemini BioProducts, West Sacramento, CA), 100U/mL penicillin, 100 µg/mL streptomycin, and 1X 
NEAA. T47D cells were cultured in RPMI (Corning, Tewksbury, MA) with 10% FBS, 100U/mL 
penicillin, 100 µg/mL streptomycin, and 1X NEAA. For studies using hormone and growth factor-
reduced conditions, cells were cultured in phenol red-free media supplemented with 5% charcoal-
stripped FBS. Cells were maintained in a 37C incubator with 5% CO2.  
 
Generation of ESR1 mutant cell lines 
 CRISPR/Cas9 knock-in was performed as previously described.2 To introduce point mutations 
into the endogenous ER locus in MCF-7 and T47D cell lines, we first constructed sgRNA vectors 
based on px458.3 Based on the corresponding sgRNA sequence, we then synthesized anti-sense 
oligonucleotide(s) (ssODNs) with the intended mutation as well as silent mutations that serve to 
prevent Cas9 re-cutting and facilitate screening.  
For each ER mutation site, the sgRNA vector (7 μg) and corresponding ssODN template (3 μl 
of 100 μM) were electroporated into cells using the Neon electroporation system from 
LifeTechnologies. GFP+ cells were subsequently sorted on an Aria III (Cytometry and Cell Sorting 
Core) and plated into 96-well plates for further culturing and screening analysis.  
Individual clones that grew back were expanded for genomic DNA extraction and PCR 
amplification of the regions that encompass each intended KI site. Successful KI of each mutation 
was confirmed by Sanger sequencing of the PCR products. sgRNA sequence for Y537S:  5’-
TCCAGCAGCAGGTCATAGAG. The sequence for the anti-sense ssODNs for the Y537S mutation is: 
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5’cctccacggctagtgggcgcatgtaggcggtgggcgtccagcatctccagcagcagAtcaGaCaggggTaccacgttcttgcacttcat
gctgtacagatgctccatgcctttgttactgt (intended mutation in bold silent mutations in italics) 
 
 MCF-7 LTED cells were generated by culturing MCF-7 cells in phenol red-free MEM media 
supplemented with 5% charcoal-stripped FBS, 100 U/mL penicillin, 100 µg/mL streptomycin, and 1X 
NEAA for six months. 
 
Subcellular Fractionation 
 MCF-7 and T47D cells were cultured in 5% charcoal-stripped FBS supplemented media for 72 
hours prior to harvesting. Cellular fractionation was performed using the Thermo Scientific Subcellular 
Protein Fractionation Kit (Thermo Fisher Cat No. PI78840) using the manufacture’s protocol. 
Cytoplasmic and nuclear fractions were analyzed by immunoblot. 
 
Digital Droplet PCR (ddPCR) 
ddPCR primer/probe sets for ESR1 were used to detect ESR1 mutations in MCF-7 LTED cells 
using the BioRad QX100TM Droplet DigitalTM PCR system as previously described.4 ESR1 Y537C ID 
dHsaMDS732897750, Y537N ID dHsaMDS296069817, ESR1 Y537S ID dHsaMDS975379796, 
D538G ID dHsaMDS460485301. Detection of 3 out of 1000 positive ESR1 mutant droplets was 
defined as positive detection of ESR1 mutation. 
 
Microarray Analysis 
To determine the hormone-independent transcriptome of MCF-7 ESR1 WT, ESR1 Y537S, and 
LTED cells, cells were plated in regular serum-containing media for 24 hours and then starved for 48 
hours in 5% charcoal-stripped serum. For MCF-7 ESR1 WT and ESR1 Y537S PalbR models, cells 
were plated in regular serum-containing media for 72 hours. RNA was extracted using the RNeasy kit 
(Qiagen, Germantown, MD). Labeled cRNA was hybridized onto Affymetrix GeneChip Human 
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Genome U133 Plus 2.0 Arrays (Life Technologies, Carlsbad, CA) in triplicate. Microarray data were 
processed using two different methods. First, expression values were estimated using RMA (Robust 
Multi-array Average) method. Group comparison was run using ANOVA analysis performed with 
Partek Genomics Suite software (www.partek.com/softwareoverview). Differentially expressed genes 
with fold >1.5 and P value <0.05 were used for GSEA and MSigDB analysis 
(http://software.broadinstitute.org/gsea/msigdb) (HALLMARK gene sets). Probe intensities were 
normalized using RMA (Robust Multi-Array Average) method. The mean of individual probes 
belonging to the same gene were used for GSEA analyses. ‘BiomaRt’ R package was used to 
convert the probe ID to HGNC (HUGO Gene Nomenclature Committee) gene symbols. The 
differential gene expression analysis was performed with ‘limma’ R package.  
 
ChIP-seq 
ChIP-Seq experiments were conducted as described previously, and were done in triplicate.5 
Briefly, chromatin from approximately 1 × 107 fixed cells, cultured in 5% CSS media was sonicated 
using Bioruptor Standard Sonicator (Diagenode) to a size range of 200-600 bp. Solubilized chromatin 
was subjected to immunoprecipitation with the ER antibody HC-20 (Santa Cruz Biotechnology, Dallas, 
TX). A fraction of the sample was not exposed to antibody to be used as control (input). The samples 
were reverse-crosslinked, treated with proteinase K, and DNA was purified. Subsequent library 
construction with the TruSeq ChIP Library Preparation Kit (Illumina) and sequencing on the NextSeq 
500 (Illumina) of the purified input and immunoprecipitated DNA were conducted by the UT 
Southwestern McDermott Sequencing Core. ER ChIP-Sequencing data was assessed for quality 
using FastQC (https://www.bioinformatics.babraham.ac.uk/projects/fastqc/) and mapped using 
Bowtie26 to the human genome build UCSC hg38. Enriched regions were determined using MACS2 
software 7 with significance achieved at q<0.05. Peak overlaps were determined using BEDTools.8 
Genes associated with peaks were determined using BEDTools and the GENCODE9 gene model. 
Signal density plots for ChIP-Seq signals were generated using the HOMER software suite10 and 
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visualized using Python scientific libraries. Signal tracks were generated using BEDTools, and 
visualized using the UCSC genome browser11 and the Integrated Genome Viewer (IGV).12 
 
ChIP-PCR 
ChIP assay was modified from a previously described method.13 Y537S cells were plated at 4 
x 106 cells per 10 cm plate in duplicate and cultured in MEM supplemented with 10% (v/v) FBS 
overnight. Cells were washed with PBS and serum starved in 10 mL of phenol red-free MEM 
supplemented with 5% (v/v) CSS for 48 hrs. Cells were crosslinked with 0.75% (v/v) formaldehyde for 
10 min at room temperature and crosslinking was quenched with 0.125 mM glycine for 5 min. Cells 
were washed with cold PBS twice and collected in 1 mL of PBS containing protease inhibitors 
(cOmplete™ Mini EDTA-free Protease Inhibitor Cocktail, Sigma). Cells were pelleted and re-
suspended in a 1:1 ratio of lysis buffer (1% sodium dodecyl sulfate (SDS), 10 mM EDTA, 50 mM Tris-
HCl, pH 8.0.) and PBS supplemented with protease inhibitors. Chromatin was fragmented using a 
Branson sonicator (Branson Ultrasonics, Danbury, CT, model S450D) to achieve a DNA fragment 
size in the range of 200-500 bp. Fragmented soluble chromatin was diluted 5-fold with dilution buffer 
(0.55% Triton X-100, 1.2 mM EDTA, 16.7 mM Tris-HCl, pH 8.0, 167 mM NaCl) and 5 % was reserved 
as the input fraction. The remaining lysate was precleared with 25 µL of 1:1 mixture of Protein-A and -
G Dynabeads (Invitrogen, Life Technologies). Soluble chromatin was immunoprecipitated overnight at 
4 ºC with 4 μg of ERα (Millipore, 06-935) or rabbit anti-mouse IgG (Invitrogen, Life Technologies). 
 Immunoprecipitated complexes were captured by incubating each sample with 50 μL of a 1:1 
mixture of Protein-A and -G Dynabeads at 4 ºC with rotation for 2 hrs. Precipitates were each washed 
sequentially for 10 minutes twice with cold low salt buffer (0.1% SDS, 1% Triton X-100, 20 mM Tris-
HCl, pH 8.0, 150 mM NaCl.) and then high salt buffer (0.1% SDS, 1% Triton X-100, 20 mM Tris-HCl, 
pH 8.0, 500 mM NaCl). Precipitates were then washed three times with cold TE and extracted three 
times with elution buffer (1% SDS, 0.1 M NaHCO3). Filtered 1 M NaHCO3 was added to the input 
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samples to a final concentration of 0.1M NaHCO3. Input and eluted protein-DNA complexes were de-
crosslinked for 6 hrs at 65 ºC and DNA was purified with QIAquick spin columns (QIAGEN). 
Enrichment of DNA fragments after ChIP was measured by qPCR in triplicate using the primer 
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